Business Context and Reporting Period
Company: BillionToOne, Inc. (BLLN)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2025
Overview: BillionToOne is a precision diagnostics company utilizing a proprietary single-molecule next-generation sequencing (smNGS) platform to detect and quantify genetic targets in cell-free DNA (cfDNA). The company operates in two primary segments: prenatal testing (UNITY portfolio) and oncology liquid biopsy (Northstar portfolio). The company completed its Initial Public Offering (IPO) on November 7, 2025, listing on the Nasdaq Global Select Market.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $305,112 | $152,582 | +100% |
| Gross Profit | $208,458 | $80,915 | +158% |
| Gross Margin | 68% | 53% | +15 pts |
| Net Income (Loss) | $7,454 | $(41,570) | Turnaround to Profit |
| Operating Income (Loss) | $16,023 | $(47,146) | Turnaround to Profit |
| Cash and Cash Equivalents | $495,975 | $191,477 | N/A |
| Long-Term Debt | $57,226 | $51,481 | N/A |
| Test Volume (Delivered) | ~610,000 | ~405,000 | +51% |
Note: Revenue is driven by a 51% increase in test volume and a 35% increase in Average Selling Price (ASP). The company achieved GAAP net income for the first time in 2025.
Material Changes vs. Prior Period
- Profitability: The company transitioned from a net loss of $41.6 million in 2024 to a net income of $7.5 million in 2025. Operating income improved from a loss of $47.1 million to a profit of $16.0 million.
- Revenue Growth: Revenue doubled to $305.1 million, driven by the expansion of the prenatal sales force and the commercial launch of oncology tests (Northstar Select and Northstar Response).
- Capital Structure: The company completed an IPO in November 2025, raising approximately $286.9 million in net proceeds. All outstanding redeemable convertible preferred stock was converted to Class A common stock.
- Debt Obligations: The company entered a new Note Purchase Agreement with Oberland Capital in August 2024. As of December 31, 2025, $50 million was drawn, and the company is obligated to sell an additional $30 million tranche by March 31, 2026, having met revenue and gross margin thresholds.
- Reimbursement: Northstar Select received Medicare coverage via the MolDX program in April 2025, contributing to ASP growth.
Guidance, Outlook, and Risks
Outlook and Strategy
- Product Pipeline: The company plans to launch a tissue-free, pan-cancer Minimal Residual Disease (MRD) test in Q4 2026. It is also developing early-stage cancer detection capabilities.
- Commercial Expansion: Strategy focuses on expanding the sales force (currently 231 representatives), increasing in-network payor contracts, and driving adoption of the UNITY Complete and Northstar portfolios.
- Facilities: A new 220,000 sq. ft. facility in Austin, Texas, is leased and expected to commence operations in 2028, tripling current testing capacity.
- Partnerships: A global partnership with Johnson & Johnson involves the UNITY Fetal Antigen CTA in the AZALEA Phase 3 clinical trial, with potential for a companion diagnostic indication.
Risks and Contingencies
- Internal Controls: The company identified material weaknesses in internal control over financial reporting (ICFR) related to the control environment, financial instrument accounting, and user access controls. These remain unremediated as of December 31, 2025, though remediation efforts are ongoing.
- Reimbursement Dependency: Over 90% of revenue is derived from third-party payors. Changes in coverage policies, denial rates, or reimbursement rates could materially impact financial results.
- Regulatory Environment: The company's tests are currently Laboratory Developed Tests (LDTs). Future FDA enforcement actions regarding LDTs could require costly premarket approvals.
- Debt Covenants: The Oberland Capital debt agreement includes restrictive covenants regarding revenue and gross margin thresholds. Failure to meet these could trigger an event of default.
Key Facts for Investor Verification
- Remediation of Material Weaknesses: Verify the progress and timeline for remediating the identified material weaknesses in internal controls over financial reporting, as this impacts the reliability of future financial reporting.
- Debt Tranche Obligation: Confirm the execution of the mandatory $30 million debt tranche sale with Oberland Capital required by March 31, 2026.
- Reimbursement Trends: Monitor the success of Medicare coverage applications for the Northstar Response test and the stability of ASPs as the company transitions more payors to in-network status.
- Product Launch Timelines: Track the commercial availability of the MRD test (expected Q4 2026) and the results of the NORTH clinical study (expected 2026).
- Operating Leverage: Assess whether the company can maintain its 68% gross margin as it scales operations and expands its sales force significantly.